There are two main ways to address uncertainty relating to clinical and/or costeffectiveness.
The first is to grant reimbursement for a limited time period during which
additional evidence on the drug effectiveness will be collected and to update the
reimbursement decision afterwards based on the new cost-effectiveness results.